mRNA therapy for myocardial infarction: A review of targets and delivery vehicles.
mRNA therapy for myocardial infarction: A review of targets and delivery vehicles.
复制标题
DOI：
10.3389/fbioe.2022.1037051
复制
发表时间：
2022
影响因子：
5.7
通讯作者：
Senyo, Samuel E. E.
中科院分区：
文献类型：
--
作者：
Wang, Xinming;Wu, Douglas H. H.;Senyo, Samuel E. E.
心血管疾病是世界上主要的死亡原因。这部分是由于成年人心脏的再生能力较低。mRNA治疗是一种正在开发的用于心脏疾病的有前途的方法。在mRNA治疗中，靶蛋白的表达通过递送合成mRNA来调节。mRNA治疗通过增加心肌细胞增殖、减少纤维化和促进血管生成而有益于心脏再生。由于mRNA在细胞质中翻译，mRNA进入细胞质和细胞核的递送效率显著影响其治疗功效。为了提高递送效率，已经开发了非病毒载体，例如脂质纳米颗粒。非病毒载体可以保护mRNA免受酶促降解，并促进mRNA的细胞内化。除了非病毒载体之外，病毒载体已经被设计成将mRNA模板递送到心脏细胞中。本文综述了脂质纳米颗粒，聚合物纳米颗粒，和病毒载体，已被用来提供mRNA进入心脏。由于对脂质纳米颗粒的兴趣越来越大，本文讨论了用于心脏mRNA递送的脂质纳米颗粒的最新进展。此外，对心肌梗死mRNA治疗的潜在靶点进行了讨论。分析了已在心脏病患者中研究的基因疗法。从临床相关的角度回顾mRNA治疗可以揭示未来研究的需求。
Cardiovascular diseases are the leading cause of death in the world. This is partly due to the low regenerative capacity of adult hearts. mRNA therapy is a promising approach under development for cardiac diseases. In mRNA therapy, expression of the target protein is modulated by delivering synthetic mRNA. mRNA therapy benefits cardiac regeneration by increasing cardiomyocyte proliferation, reducing fibrosis, and promoting angiogenesis. Because mRNA is translated in the cytoplasm, the delivery efficiency of mRNA into the cytoplasm and nucleus significantly affects its therapeutic efficacy. To improve delivery efficiency, non-viral vehicles such as lipid nanoparticles have been developed. Non-viral vehicles can protect mRNA from enzymatic degradation and facilitate the cellular internalization of mRNA. In addition to non-viral vehicles, viral vectors have been designed to deliver mRNA templates into cardiac cells. This article reviews lipid nanoparticles, polymer nanoparticles, and viral vectors that have been utilized to deliver mRNA into the heart. Because of the growing interest in lipid nanoparticles, recent advances in lipid nanoparticles designed for cardiac mRNA delivery are discussed. Besides, potential targets of mRNA therapy for myocardial infarction are discussed. Gene therapies that have been investigated in patients with cardiac diseases are analyzed. Reviewing mRNA therapy from a clinically relevant perspective can reveal needs for future investigations.
登录
查看更多内容
DOI：
10.3390/nano12193423
发表时间：
2022-09-29
期刊：
Nanomaterials (Basel, Switzerland)
影响因子：
--
作者：
Andrée L;Oude Egberink R;Dodemont J;Hassani Besheli N;Yang F;Brock R;Leeuwenburgh SCG
通讯作者：
Leeuwenburgh SCG
影响因子：
64.5
作者：
Bersell, Kevin;Arab, Shima;Kuehn, Bernhard
通讯作者：
Kuehn, Bernhard
影响因子：
2.3
作者：
Connolly B;Isaacs C;Cheng L;Asrani KH;Subramanian RR
通讯作者：
Subramanian RR
影响因子：
8
作者：
Babiker，Fawzi;Benter，Ibrahim F.;Akhtar，Saghir
通讯作者：
Akhtar，Saghir
DOI：
10.1038/mtna.2013.2
发表时间：
2013-03-05
期刊：
Molecular therapy. Nucleic acids
影响因子：
--
作者：
通讯作者：
--